Candida peptide-Human Leukocyte Antigen complex (Candida pHLA)

Candida peptide antigens presented on Human Leukocyte Antigen (HLA) molecules represent a critical interface between the fungal pathogen and the host immune system. These complexes consist of short peptide fragments derived from Candida proteins, such as Agglutinin-like sequence 3 (Als3) or Hyphal wall protein 1 (Hwp1), which are processed and loaded onto HLA Class I or Class II molecules for presentation to T-cell receptors (TCRs) [1][2]. This presentation is essential for the activation of CD4+ helper T cells and CD8+ cytotoxic T cells, which coordinate the clearance of fungal infections through the release of cytokines like IFN-gamma and IL-17 [3]. In the context of disease, these pHLA complexes are the primary targets for the development of immunotherapies, including vaccines like NDV-3A and adoptive T-cell transfers, particularly for immunocompromised patients suffering from invasive candidiasis [4]. Therapeutic strategies aim to enhance the recognition of these specific complexes to elicit a robust and targeted antifungal response. However, challenges include the high polymorphism of HLA alleles across populations and the potential for cross-reactivity with human self-peptides, which could lead to off-target effects [3][4]. Sources: [1] Schmidt et al. (2012) Vaccine; [2] Bacher et al. (2014) Journal of Immunology; [3] Potenza et al. (2021) Journal of Fungi; [4] Edwards et al. (2018) Clinical Infectious Diseases.

Other names

Candida peptide-MHC complexCandida-specific T-cell epitopesCandida antigen-HLA complexCandida albicans peptide-HLA complex

Induction of T-cell mediated immunity through the recognition of fungal peptides presented by HLA molecules, leading to targeted fungal cell lysis and cytokine-mediated immune recruitment.